Record Details

Landmark Pharma Patent Jurisprudence in India

Online Publishing @ NISCAIR

View Archive Info
 
 
Field Value
 
Authentication Code dc
 
Title Statement Landmark Pharma Patent Jurisprudence in India
 
Added Entry - Uncontrolled Name Nair, Gopakumar G; Gopakumar Nair Associates
 
Uncontrolled Index Term Gleevec,Section 3(d), Supreme Court order, IPAB, Erlotinib, Sitagliptin, Sorafenib,Dasatinib, Sunitinib, Date of Patent, ordinarily, in effect, per se.
 
Summary, etc. In a short span of less than 10years after the new WTO/TRIPS based patent regime came into effect, there havebeen many landmark judgments from Indian Courts on interpretation of variousprovisions of the exhaustive (Indian) Patents Act, 1970, as amended. Eventhough, India has granted very large number of Patents during this period, thechallenges were limited to a few blockbuster molecules. Further litigations arein progress. The landmark cases in recent times are dealt with herein.Additional areas which may require judicial intervention is also briefly dealtwith.
 
Publication, Distribution, Etc. Journal of Intellectual Property Rights (JIPR)
2023-04-03 16:34:26
 
Electronic Location and Access application/pdf
http://op.niscair.res.in/index.php/JIPR/article/view/3493
 
Data Source Entry Journal of Intellectual Property Rights (JIPR); ##issue.vol## 19, ##issue.no## 2 (2014): Journal of Intellectual Property Rights
 
Language Note en
 
Nonspecific Relationship Entry http://op.niscair.res.in/index.php/JIPR/article/download/3493/6751